Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Rahway › NPI 1861486870
Hospital

Robert Wood Johnson University Hospital at Rahway

Robert Wood Johnson University Hospital at Rahway was paid $28.38M by Medicaid between Jan 2018 and Dec 2024, across 222 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.

33Billing provider infoROBERT WOOD JOHNSON UNIVERSITY HOSPITAL AT RAHWAY
RAHWAY, NJ 07065
33aNPI1861486870assigned 09/06/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.38M
24GClaims635,397
24DCodes billed222
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in New Jersey

Rank by total paid#50 of 93
Median peer was paid$30.60M
This provider vs. median0.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201887,435$4.32M
201991,425$3.91M
202058,705$2.38M
202175,986$2.92M
2022100,473$3.51M
2023123,311$5.93M
2024incomplete98,062$5.41M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 19% 24,484 22,883 $5.28M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 18% 21,804 20,296 $5.23M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 12% 10,319 9,369 $3.47M
G0378 Hospital observation service, per hour 12% 7,958 6,679 $3.43M
99282 Emergency department visit for the evaluation and management, low to moderate severity 4.9% 11,518 10,835 $1.38M
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 2.6% 33,075 7,150 $749K
OP250 2.4% 45,493 32,033 $691K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 1.6% 18,568 4,628 $461K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.2% 2,936 2,807 $349K
96361 Intravenous infusion, hydration; each additional hour 1.1% 8,967 7,976 $317K
OP710 1.1% 3,234 2,984 $309K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 5,624 4,968 $281K
210 more codes
96375 Therapeutic injection; each additional sequential IV push <1% 10,071 $260K
93975 <1% 2,245 $255K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 16,334 $250K
95811 <1% 115 $231K
70450 Computed tomography, head or brain; without contrast material <1% 3,982 $228K
OP270 <1% 3,635 $201K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 755 $198K
OP379 <1% 2,249 $192K
80053 Comprehensive metabolic panel <1% 27,865 $190K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 11,970 $189K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 29,983 $177K
71045 Radiologic examination, chest; single view <1% 12,225 $176K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 1,995 $175K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 1,518 $152K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 3,366 $138K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 2,857 $131K
OP370 <1% 1,194 $115K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 745 $115K
OP272 <1% 3,608 $102K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 459 $91K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 7,517 $91K
93017 <1% 713 $90K
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 3,759 $89K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 3,804 $86K
36415 Collection of venous blood by venipuncture <1% 28,611 $86K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 2,921 $85K
97010 <1% 10,744 $84K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 3,944 $84K
A0427 Emergency ambulance ride, advanced life support <1% 384 $80K
71046 Radiologic examination, chest; 2 views <1% 3,540 $76K
OP258 <1% 18,922 $75K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,661 $74K
95816 <1% 301 $70K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 1,048 $63K
97162 <1% 1,744 $61K
76830 Ultrasound, transvaginal <1% 1,109 $59K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 1,205 $57K
84484 <1% 9,254 $55K
72125 Computed tomography, cervical spine; without contrast material <1% 658 $52K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 1,699 $51K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,117 $50K
83735 <1% 13,435 $45K
97164 <1% 1,312 $44K
OP279 <1% 7,612 $42K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 712 $40K
84443 Thyroid stimulating hormone (TSH) <1% 3,645 $39K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 2,306 $36K
85610 <1% 10,233 $36K
73630 <1% 1,767 $35K
85730 <1% 9,199 $34K
82962 <1% 6,067 $30K
83880 <1% 2,459 $29K
88312 <1% 678 $29K
73130 <1% 1,241 $28K
83690 <1% 9,778 $28K
73610 <1% 1,429 $27K
93971 <1% 391 $25K
88313 <1% 703 $25K
82150 <1% 5,803 $23K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 413 $21K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,876 $21K
86803 <1% 3,764 $21K
80061 Lipid panel <1% 2,172 $21K
73562 <1% 959 $21K
84702 <1% 3,685 $21K
73030 <1% 933 $20K
97113 <1% 340 $19K
0240U <1% 579 $19K
71275 Computed tomographic angiography, chest, with contrast material <1% 150 $19K
81001 <1% 6,743 $18K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 708 $18K
77063 Screening digital breast tomosynthesis, bilateral <1% 573 $16K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 417 $16K
80048 Basic metabolic panel (calcium, ionized) <1% 2,924 $16K
97161 <1% 397 $16K
84100 <1% 3,398 $15K
86901 <1% 2,058 $14K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 978 $14K
81025 <1% 5,806 $14K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 335 $13K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,552 $13K
82550 <1% 3,294 $13K
86900 <1% 2,058 $13K
87040 <1% 1,418 $12K
86850 <1% 1,942 $12K
96376 <1% 1,094 $12K
83036 Hemoglobin; glycosylated (A1C) <1% 1,881 $11K
81003 <1% 7,117 $11K
A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose <1% 496 $10K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 756 $10K
S9480 Intensive outpatient psychiatric services, per diem <1% 14 $10K
97014 <1% 1,407 $10K
73110 <1% 475 $9K
90715 <1% 1,116 $9K
83605 <1% 1,373 $9K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 562 $9K
97116 <1% 562 $9K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 380 $9K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 756 $8K
87186 <1% 1,416 $8K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 1,336 $7K
12001 <1% 116 $7K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 747 $7K
87070 <1% 1,207 $7K
A0425 Ground mileage, per statute mile <1% 409 $7K
96367 <1% 372 $6K
97163 <1% 159 $6K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,352 $5K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 192 $5K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 24 $5K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 5,430 $5K
93970 <1% 55 $4K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 131 $4K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 230 $4K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 19 $4K
J2704 Injection, propofol, 10 mg <1% 1,862 $4K
73564 <1% 260 $4K
82607 <1% 327 $4K
87340 <1% 1,056 $4K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 8,273 $4K
G0270 Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes <1% 164 $4K
10060 <1% 66 $3K
70551 Magnetic resonance imaging, brain; without contrast material <1% 14 $3K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 539 $3K
84439 <1% 655 $3K
0002A <1% 82 $3K
J2785 Injection, regadenoson, 0.1 mg <1% 55 $3K
A9270 Non-covered item or service <1% 4,950 $3K
84436 <1% 725 $3K
0001A <1% 76 $3K
72110 <1% 50 $2K
85027 <1% 1,147 $2K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,409 $2K
99213 Doctor's office visit, returning patient (routine) <1% 74 $2K
73502 <1% 85 $2K
88304 <1% 119 $2K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 2,109 $2K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 684 $2K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 985 $2K
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 176 $2K
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 168 $2K
85378 <1% 422 $1K
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 13 $1K
J1756 Injection, iron sucrose, 1 mg <1% 46 $1K
80305 <1% 444 $1K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 1,864 $1K
71101 <1% 57 $1K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 51 $1K
85379 <1% 500 $1K
12011 <1% 44 $1K
73140 <1% 28 $1K
85007 <1% 911 $945.94
45384 <1% 12 $859.82
84479 <1% 245 $827.41
87088 <1% 534 $801.50
73590 <1% 63 $735.35
74021 <1% 25 $729.14
J0500 Injection, dicyclomine hcl, up to 20 mg <1% 140 $698.65
87077 <1% 183 $655.43
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 817 $628.00
15853 <1% 12 $523.32
J0690 Injection, cefazolin sodium, 500 mg <1% 150 $473.08
87807 <1% 199 $454.71
76770 <1% 12 $433.46
74018 <1% 41 $415.07
OP637 <1% 803 $401.55
J3475 Injection, magnesium sulfate, per 500 mg <1% 424 $387.65
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 251 $375.05
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 382 $370.39
99203 Doctor's office visit, new patient (routine) <1% 13 $366.30
97535 Self-care/home management training, each 15 minutes <1% 16 $342.08
Q9963 High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml <1% 369 $313.93
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 17 $293.73
87081 <1% 105 $277.22
J2270 Injection, morphine sulfate, up to 10 mg <1% 475 $277.02
87205 <1% 135 $260.44
94664 <1% 14 $243.39
97803 <1% 12 $242.40
87147 <1% 39 $196.88
J3010 Injection, fentanyl citrate, 0.1 mg <1% 506 $178.37
80320 <1% 114 $172.85
82728 <1% 14 $168.06
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 126 $156.45
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 28 $145.48
76857 <1% 12 $141.02
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 12 $132.57
82746 <1% 13 $113.81
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 288 $108.81
86140 <1% 42 $95.71
J2920 Injection, methylprednisolone sodium succinate, up to 40 mg <1% 84 $94.44
83550 <1% 14 $79.47
81002 <1% 262 $79.27
J1170 Injection, hydromorphone, up to 4 mg <1% 108 $66.50
82553 <1% 14 $61.49
83540 <1% 14 $52.53
85651 <1% 38 $48.70
82248 <1% 14 $43.50
J0137 Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg <1% 32 $43.12
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 16 $34.20
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg <1% 20 $32.06
J2060 Injection, lorazepam, 2 mg <1% 97 $27.40
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 48 $26.31
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 59 $25.84
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 15 $19.90
85652 <1% 15 $15.35
J1171 Injection, hydromorphone, 0.1 mg <1% 18 $13.00
J1630 Injection, haloperidol, up to 5 mg <1% 32 $9.85
81015 <1% 33 $7.17
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 84 $1.00
J0687 Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDUNN, RODNEY (CFO)
Parent organizationRWJ BARNABAS HEALTH INC